Home > News > Abraxis BioScience: A SPARC for Explosive Growth?
July 20th, 2006
Abraxis BioScience: A SPARC for Explosive Growth?
Abstract:
Abraxis BioScience, Inc. (ABBI) provides a unique opportunity for investment in a biopharmaceutical company that is revolutionizing cancer therapy with its proprietary nanotechnology platform. Abraxis’ nanoparticle albumin-bound, or nab technology, exploits the natural properties of a human protein, albumin, for drug delivery.
Source:
seekingalpha.com
Bookmark:
| Related News Press |
Investments/IPO's/Splits
Nanometrics Announces Upcoming Investor Events August 3rd, 2017
Nanomedicine
Gold nanostars and immunotherapy vaccinate mice against cancer: New treatment cures, vaccinates mouse in small proof-of-concept study August 18th, 2017
Freeze-dried foam soaks up carbon dioxide: Rice University scientists lead effort to make novel 3-D material August 16th, 2017
Two Scientists Receive Grants to Develop New Materials: Chad Mirkin and Monica Olvera de la Cruz recognized by Sherman Fairchild Foundation August 16th, 2017
Profiles
Russia’s Nano-enabled Products Market to Witness Massive Growth February 8th, 2011
Adept Technology Announces Orders for Over $600K from Chinese Partner January 18th, 2011
Nanostart-held ItN Nanovation Receives Major Follow-on Order in Saudi Arabia November 29th, 2010
Homegrown Companies Developing Batteries for Clean Energy Storage November 2nd, 2010
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
University Technology Transfer & Patents
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||